Dr. DiMarchi became a director in July 2014 upon the closing of the acquisition of Assembly Pharmaceuticals, which he co-founded and served as a founding director. Dr. DiMarchi currently holds the Cox Distinguished Professor of Biochemistry and Gill Chair in Biomolecular Sciences at Indiana University and serves as a research director at Novo Nordisk Research Labs. Dr. DiMarchi was a co-founder and board member of biotechnology companies Ambrx, Marcadia and Calibrium Biotech, and advisor to venture firms 5AM, Twilight Ventures and others. Dr. DiMarchi retired as Group Vice President at Eli Lilly and Co., where he provided leadership for more than two decades in biotechnology, endocrine research and product development. Dr. DiMarchi previously served as a director of Isis and Millennium BioTherapeutics, as well as board member of the biotechnology trade group BIO. Dr. DiMarchi contributed significantly to the discovery of the first insulin analog, Humalog®, and to the commercial development of major pharmaceutical products such as Humulin®, Humatrope®, Glucagon®, Xigris®, Forteo® and Evista®. He is the recipient of numerous awards and has been inducted into the National Inventors Hall of Fame and the National Academy of Medicine. Dr. DiMarchi received a BS with honors from Florida Atlantic University and a PhD in Biochemistry from Indiana University. He completed postdoctoral studies at the Rockefeller University.